ClinicalTrials.gg
Status unknownNCT04010838Updated Jul 8, 2019

Spinal Cord Stimulation in Patients With Disorders of Consciousness

An interventional study of spinal cord stimulation in Disorder of Consciousness, Minimally Conscious State and Vegetative State, sponsored by Huashan Hospital. Status unknown at 1 site in China. Open to participants aged 14 Years to 65 Years. Per ClinicalTrials.gov, last updated 2019-07-08.

Sponsored by Huashan Hospital · Not applicable, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Jul 2019), so the status shown — last known as Recruiting — may be out of date.
Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
14 Years to 65 Years
Sex
All
01

Study summary

Disorders of consciousness(DOC) is the most serious complications and has been widely paid attention to by the government. DOC patients cause large social and economic burden to our society for there has no effective cure so far. Spinal cord stimulation(SCS) for wake-promoting therapy has aroused scholars' attention and become a hot area recently. There was much debate about the effectiveness of SCS therapy, but because of the limitation of our understanding of consciousness and the uncertainty of parameters of the stimulation, So, to figure out the indications and effectiveness of neuromodulation therapy should be the first step, and finding individual treatment and parameter may have important implications for DOC patients.

Read the detailed description

The spinal cord stimulation therapy is explorative at best at the moment. Attempts to improve the level of consciousness of patients in the different stages of DOC have shown some promise. Spinal cord stimulation(SCS) seem promising in some studies, suggesting that further research is needed. Current publications of DOC spinal cord stimulation therapy was not convincing because of the small number of patients and no randomized controlled trial. Therefore, there was much debate about the effectiveness of spinal cord stimulation therapy because of the limitation of our understanding of consciousness and the uncertainty of parameters of neuromodulation. The better understanding of brain function and large randomized trials are necessary. Future research should also focus on identifying specific neuro-biomarkers (i.e. neural network). So, to figure out the indications and effectiveness of neuromodulation therapy should be the first step, and finding individual treatment and parameter may have important implications for DOC patients.

Scientific Issues Targeted:1) To figure out the effectiveness of spinal cord stimulation therapy using random controlled trial. 2) To explore individual parameters of SCS techniques.

02

Conditions studied

  • Disorder of Consciousness
  • Minimally Conscious State
  • Vegetative State

Keywords

  • disorders of consciousness
  • spinal cord stimulation
  • DoC
  • SCS
03

In context

Consciousness Disorders

290 studies on the registry are indexed under Consciousness Disorders; 109 are open to participants now.

This study's planned enrollment of 40 is below the median of 47 across 191 interventional studies indexed under Consciousness Disorders.

Browse Consciousness Disorders studies →

Lead sponsor

Huashan Hospital is the lead sponsor of 247 studies on the registry; 104 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
14 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients ages 14 to 65 years old;
  2. DOC patients, including vegetative state and minimally consciousness state.
  3. With normal body temperature, stable vital signs, spontaneous breathing without an extra oxygen supply, no tracheotomy using metal trachea cannula, and feasible for magnetic resonance inspectors;
  4. Written from patient families

Exclusion criteria

Exclusion Criteria:

  1. History of nervous or spirit disorders, or some other serious diseases such as cardiac or pulmonary problems;
  2. With of spinal cord operations.
  3. Body temperature is abnormal, vital signs are not stable, still need a ventilator to support breathing; Plentiful sputum needed suction during MRI scans.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
40 participants (estimated)

Study arms

  • No intervention
    Conventional treatment
  • Experimental
    Spinal cord stimulation and conventional treatment

    Procedure: spinal cord stimulation

Interventions

  • Procedurespinal cord stimulation

    The spinal cord stimulation(SCS) is a type of implantable neuromodulation device (spinal cord stimulator) that is used to send electrical signals to select areas of the spinal cord (C2-C4 in this study) for the treatment of disorders of consciousness.

06

What researchers measure

Primary outcomes

  1. the JFK Coma Recovery Scale-Revised (CRS-R) scale

    The CRS-R is a tool used to characterise the level of consciousness.The CRS-R is a tool used to characterize the level of consciousness and to monitor neurobehavioural recovery in DOC. The scale consists of 23 hierarchically arranged items that comprise six subscales addressing the auditory, visual, motor, oromotor/verbal, communication and arousal processes. The lowest item on each subscale represents reflexive activity whereas the highest item represents cognitively mediated behaviors.

    Time frame: at baseline (T0), which means 1 month before stimulation.

  2. the JFK Coma Recovery Scale-Revised (CRS-R) scale

    The CRS-R is a tool used to characterise the level of consciousness.The CRS-R is a tool used to characterize the level of consciousness and to monitor neurobehavioural recovery in DOC. The scale consists of 23 hierarchically arranged items that comprise six subscales addressing the auditory, visual, motor, oromotor/verbal, communication and arousal processes. The lowest item on each subscale represents reflexive activity whereas the highest item represents cognitively mediated behaviors.

    Time frame: 2 weeks after the end of the treatment (T1)

  3. the JFK Coma Recovery Scale-Revised (CRS-R) scale

    The CRS-R is a tool used to characterise the level of consciousness.The CRS-R is a tool used to characterize the level of consciousness and to monitor neurobehavioural recovery in DOC. The scale consists of 23 hierarchically arranged items that comprise six subscales addressing the auditory, visual, motor, oromotor/verbal, communication and arousal processes. The lowest item on each subscale represents reflexive activity whereas the highest item represents cognitively mediated behaviors.

    Time frame: 3 months after the end of the treatment (T2)

  4. the JFK Coma Recovery Scale-Revised (CRS-R) scale

    The CRS-R is a tool used to characterise the level of consciousness.The CRS-R is a tool used to characterize the level of consciousness and to monitor neurobehavioural recovery in DOC. The scale consists of 23 hierarchically arranged items that comprise six subscales addressing the auditory, visual, motor, oromotor/verbal, communication and arousal processes. The lowest item on each subscale represents reflexive activity whereas the highest item represents cognitively mediated behaviors.

    Time frame: 6 months after the end of the treatment(T3)

Secondary outcomes

  1. EEG recording in resting state with Phase Coherence analysis(PC index)

    EEG data will be collected using a 256-channel EEG recording system(GES300, Electrical Geodesic, Inc., USA). Phase Coherence index will be performed in MATLAB by first taking the phase of the spectral signals(A), and the caculating as the following: mean\[cos(A),2\]\^2 + mean\[sin(A),2\]\^2

    Time frame: at baseline (T0), which means 1 month before stimulation.

  2. EEG recording in resting state with Phase Coherence analysis(PC index)

    EEG data will be collected using a 256-channel EEG recording system(GES300, Electrical Geodesic, Inc., USA). Phase Coherence index will be performed in MATLAB by first taking the phase of the spectral signals(A), and the caculating as the following: mean\[cos(A),2\]\^2 + mean\[sin(A),2\]\^2

    Time frame: 2 weeks after the end of the treatment (T1)

  3. EEG recording in resting state with Phase Coherence analysis(PC index)

    EEG data will be collected using a 256-channel EEG recording system(GES300, Electrical Geodesic, Inc., USA). Phase Coherence index will be performed in MATLAB by first taking the phase of the spectral signals(A), and the caculating as the following: mean\[cos(A),2\]\^2 + mean\[sin(A),2\]\^2

    Time frame: 3 months after the end of the treatment (T2)

  4. EEG recording in resting state with Phase Coherence analysis(PC index)

    EEG data will be collected using a 256-channel EEG recording system(GES300, Electrical Geodesic, Inc., USA). Phase Coherence index will be performed in MATLAB by first taking the phase of the spectral signals(A), and the caculating as the following: mean\[cos(A),2\]\^2 + mean\[sin(A),2\]\^2

    Time frame: 6 months after the end of the treatment (T3)

07

Study locations

1 of 1 sites recruiting
  • Department of Neurosurgery, Huashan Hospital
    Shanghai, Shanghai 200000, China
    Recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jul 2019; primary completion for Dec 2021, 29 months later.

Of 89 non-industry interventional studies with no phase under Consciousness Disorders, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 52. This study's planned 29 months is above that.

Counting every sponsor, half of 94 studies reached it within 19 months; a quarter within 8 and three quarters within 52.

How these figures are worked out, and which studies are left out of them.

Registered
May 18, 2019
First posted
Jul 8, 2019
StartEst.
Jul 1, 2019
Primary completionEst.
Dec 31, 2021
CompletionEst.
Jun 30, 2023
Last update
Jul 8, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 8, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04010838
Lead sponsor
Huashan Hospital
Responsible party
Xuehai Wu (Professor, Huashan Hospital, Huashan Hospital) — Principal investigator
First posted
Jul 8, 2019
Start date
Jul 1, 2019 (estimated)
Primary completion
Dec 31, 2021 (estimated)
Completion
Jun 30, 2023 (estimated)
Last update
Jul 8, 2019

Study contacts

Xuehai Wu, Ph.D.
Contact
wuxuehai2013@163.com
+8613764880571
Ying Mao, Ph.D.
Contact
maoying@fudan.edu.cn
+862152887200

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Jul 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion